Literature DB >> 21449685

Guidelines for the development and validation of new potency assays for the evaluation of umbilical cord blood.

Stephen Spellman1, Carolyn K Hurley, Colleen Brady, Lisa Phillips-Johnson, Robert Chow, Mary Laughlin, John McMannis, Jo-Anna Reems, Donna Regan, Pablo Rubinstein, Joanne Kurtzberg.   

Abstract

The following commentary was developed by the National Marrow Donor Program Cord Blood Advisory Group and is intended to provide an overview of umbilical cord blood (UCB) processing, summarize the current state of potency assays used to characterize UCB, and define limitations of the assays and future needs of the cord blood banking and transplant community. The UCB banking industry is eager to participate in the development of standardized assays to uniformly characterize cellular therapy products that are manufactured in a variety of ways. This paper describes the desired qualities of these assays and how the industry proposes to co-operate with developers to bring relevant assays to market. To that end, the National Marrow Donor Program (NMDP) Cord Blood Bank Network is available to serve as a resource for UCB testing material, research and development consulting, and product/assay testing in an accredited UCB manufacturing environment.

Entities:  

Mesh:

Year:  2011        PMID: 21449685     DOI: 10.3109/14653249.2011.571249

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  7 in total

Review 1.  Improving Quality and Potency Testing for Umbilical Cord Blood: A New Perspective.

Authors:  Ivan N Rich
Journal:  Stem Cells Transl Med       Date:  2015-07-09       Impact factor: 6.940

2.  Dominant unit CD34+ cell dose predicts engraftment after double-unit cord blood transplantation and is influenced by bank practice.

Authors:  Duncan Purtill; Katherine Smith; Sean Devlin; Richard Meagher; Joann Tonon; Marissa Lubin; Doris M Ponce; Sergio Giralt; Nancy A Kernan; Andromachi Scaradavou; Cladd E Stevens; Juliet N Barker
Journal:  Blood       Date:  2014-09-02       Impact factor: 22.113

3.  The use of back-up units to enhance the safety of unrelated donor cord blood transplantation.

Authors:  Doris M Ponce; Marissa Lubin; Anne Marie Gonzales; Courtney Byam; Deborah Wells; Rosanna Ferrante; Glenn Heller; Sergio Giralt; Esperanza B Papadopoulos; Nancy A Kernan; Andromachi Scaradavou; Juliet N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2012-01-11       Impact factor: 5.742

4.  Current practices and prospects for standardization of the hematopoietic colony-forming unit assay: a report by the cellular therapy team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative.

Authors:  Derwood Pamphilon; Eileen Selogie; David McKenna; Jose A Cancelas-Peres; Zbigniew M Szczepiorkowski; Ron Sacher; John McMannis; Hermann Eichler; Henk Garritsen; Minoko Takanashi; Leo van de Watering; David Stroncek; Jo-Anna Reems
Journal:  Cytotherapy       Date:  2013-03       Impact factor: 5.414

5.  Analysis of the CD34+ cell to total nucleated cell content ratio of 619 transplanted and back-up cord blood units.

Authors:  Ioannis Politikos; Christopher M Mazis; Kristine A Naputo; Kelcey Skinner; Melissa Nhaissi; Eric Davis; Andromachi Scaradavou; Juliet N Barker
Journal:  Bone Marrow Transplant       Date:  2020-08-29       Impact factor: 5.483

6.  Detecting primitive hematopoietic stem cells in total nucleated and mononuclear cell fractions from umbilical cord blood segments and units.

Authors:  John Patterson; Cally H Moore; Emily Palser; Jason C Hearn; Daniela Dumitru; Holli A Harper; Ivan N Rich
Journal:  J Transl Med       Date:  2015-03-18       Impact factor: 5.531

7.  The Assessment of Parameters Affecting the Quality of Cord Blood by the Appliance of the Annexin V Staining Method and Correlation with CFU Assays.

Authors:  Teja Falk Radke; David Barbosa; Richard Charles Duggleby; Riccardo Saccardi; Sergio Querol; Gesine Kögler
Journal:  Stem Cells Int       Date:  2013-03-07       Impact factor: 5.443

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.